This clinical trial is focused on studying a group of blood disorders known as Philadelphia-negative myeloproliferative neoplasms. These disorders include Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. These conditions are chronic and involve the overproduction of blood cells. The study aims to compare the effectiveness of two types of medications in preventing blood clots in patients with these disorders who have a specific genetic mutation called JAK2V617F. The medications being tested are Apixaban and Rivaroxaban, which are known as direct oral anticoagulants (DOACs), and they will be compared to Aspirin, a commonly used medication for preventing blood clots.
The purpose of the study is to determine if low-dose DOACs are more effective than low-dose Aspirin in preventing blood clots in high-risk patients with these blood disorders. Participants in the study will be randomly assigned to receive either Apixaban, Rivaroxaban, or Aspirin. The study will monitor the time it takes for any blood clotting events to occur, as well as any significant bleeding events. The study will also look at other health outcomes, such as overall survival and quality of life, over a period of 24 months.
Throughout the study, participants will take their assigned medication orally, and their health will be closely monitored by the research team. The study will help to better understand which medication is more effective in preventing complications related to blood clots in patients with these specific blood disorders. The findings could lead to improved treatment options for individuals with these conditions.
France 
